Samelisant

Samelisant
Clinical data
Other names	SUVN-G3031
Drug class	Histamine H3 receptor inverse agonist; Wakefulness-promoting agent
Pharmacokinetic data
Elimination half-life	23-34 hours
Identifiers
	IUPAC name N-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide;
CAS Number	1394808-82-2;
PubChem CID	60151477;
IUPHAR/BPS	10232;
DrugBank	DB14835;
ChemSpider	64854818;
UNII	65V47O9NOP;
ChEMBL	ChEMBL4297328;
Chemical and physical data
Formula	C21H31N3O3
Molar mass	373.497 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)NC(=O)CN4CCOCC4;
	InChI InChI=1S/C21H31N3O3/c25-21(16-23-12-14-26-15-13-23)22-17-4-6-19(7-5-17)27-20-8-10-24(11-9-20)18-2-1-3-18/h4-7,18,20H,1-3,8-16H2,(H,22,25); Key:LNXDUSQEXVQFGP-UHFFFAOYSA-N;

Samelisant (INNTooltip International Nonproprietary Name; developmental code name SUVN-G3031) is an experimental wakefulness-promoting agent acting as a selective histamine H₃ receptor inverse agonist which is under development for the treatment of narcolepsy. It was also under development for the treatment of cognition disorders and Parkinson's disease, but no recent development has been reported for these indications. As of June 2024, samelisant is in phase 2 clinical trials for the treatment of narcolepsy.